Xencor to Present at the Jefferies Virtual Healthcare Conference

MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:00 p.m. ET / 10:00 a.m. PT.

A webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005825/en/

Charles Liles
[email protected]

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
[email protected]

Source: Xencor, Inc.

You May Also Be Interested In

• Danfoss Selects RISE with SAP and HPE GreenLake to Accelerate Sustainable Cloud Journey
• Exclusive Selections to Prepare for Summer: April Offers of Tineco
• Palliser Capital Proposes Advisory Resolution to Give Shareholders a Voice at Keisei’s Forthcoming AGM